Calls for papers
-
Seurat Therapeutics, a start-up biotech based at the University of Chicago, has received a grant of almost $510,000 from the National Institute of Neurological Disorders and Stroke for development of its intranasal IGF-1 for the… Read more . . .
-
According to AstraZeneca, the EMA’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion regarding the marketing authorization application for the company’s Bevespi Aerosphere glycopyrronium/formoterol fumarate MDI for the treatment of… Read more . . .
-
Auris Medical has announced results from a second Phase 1 study of its intranasal betahistine in 72 healthy volunteers that demonstrated superior bioavailability compared to oral betahistine for 4 doses of the nasal formulation, with… Read more . . .
-
Dry powder inhaler developer Iconovo has announced a partnership with McMaster University for development of a dry powder tuberculosis vaccine to be delivered via Iconovo’s ICOone single-dose DPI. According to the company, the ICOone inhaler… Read more . . .
-
Secarna Pharmaceuticals has announced that the Inhaled Nanocarriers with Antisense Therapy for lung fibrosis (INAT) project has received a 3-year grant to fund from the ERA-Net Cofund EuroNanoMed3, part of the EC’s Horizon 2020 Framework… Read more . . .
-
Proveris Scientific, which offers a variety of products and services related to aerosol characterization, has achieved certification to the ISO 9001:2015 quality standard through October 2021, the company said. TUV Rheinland of North America, which… Read more . . .
-
The FDA has approved labeling and indication changes for Boehringer Ingelheim’s Stiolto Respimat tiotropium/olodaterol SMI, adding data about reductions in COPD exacerbations to the label. Stiolto Respimat (marketed in Europe as Spiolto Respimat) was initially… Read more . . .
-
Janssen Pharmaceutical has submitted an MAA to the EMA for its esketamine nasal spray for the treatment of treatment-resistant depression in adults with major depressive disorder, the company said. Janssen submitted an NDA for the… Read more . . .
-
Organizers of DDL 2018 say that they are expecting over 800 OINDP specialists to attend this year’s iteration of the Drug Delivery to the Lungs meeting, to be held December 12-14 in Edinburgh, UK. According… Read more . . .
-
KAER Biotherapeutics has been awarded a $2 million Phase 2 Small Business Innovation Research (SBIR) grant by the National Heart Lung and Blood Institute of the National Institutes of Health for development of a device… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
October 28-October 30: Deutches Aerosol Therapie Symposium (DATS), Marburg, Germany